Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Cancer Research
|
February 28, 2018
Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
Liye He, Jing Tang, Emma I Andersson, et al.
Cancers
|
March 20, 2020
<i>STAT3</i> Mutation Is Associated with STAT3 Activation in CD30<sup>+</sup> ALK<sup>-</sup> ALCL
Emma I Andersson, Oscar Brück, Till Braun, et al.
Scientific Reports
|
February 9, 2018
Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8<sup>+</sup> TCR-Vβ<sup>+</sup> expansions
Anna Lissina, James E McLaren, Mette Ilander, et al.
Haematologica
|
October 5, 2014
The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia
Hanna L M Rajala, Thomas Olson, Michael J Clemente, et al.
Oncotarget
|
February 11, 2017
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
Paavo O Pietarinen, Christopher A Eide, Pilar Ayuda-Durán, et al.
Blood
|
April 19, 2013
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
Hanna L M Rajala, Samuli Eldfors, Heikki Kuusanmäki, et al.
Nature Communications
|
April 21, 2018
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
Olli Dufva, Matti Kankainen, Tiina Kelkka, et al.
Biomarker Research
|
October 28, 2020
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia
Carlos Cuesta-Mateos, Patricia Fuentes, Alexandra Schrader, et al.
The New England Journal of Medicine
|
May 18, 2012
Somatic STAT3 mutations in large granular lymphocytic leukemia
Hanna L M Koskela, Samuli Eldfors, Pekka Ellonen, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Cancer Research
|
February 28, 2018
Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients
Liye He, Jing Tang, Emma I Andersson, et al.
Cancers
|
March 20, 2020
<i>STAT3</i> Mutation Is Associated with STAT3 Activation in CD30<sup>+</sup> ALK<sup>-</sup> ALCL
Emma I Andersson, Oscar Brück, Till Braun, et al.
Scientific Reports
|
February 9, 2018
Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8<sup>+</sup> TCR-Vβ<sup>+</sup> expansions
Anna Lissina, James E McLaren, Mette Ilander, et al.
Haematologica
|
October 5, 2014
The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia
Hanna L M Rajala, Thomas Olson, Michael J Clemente, et al.
Oncotarget
|
February 11, 2017
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
Paavo O Pietarinen, Christopher A Eide, Pilar Ayuda-Durán, et al.
Blood
|
April 19, 2013
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
Hanna L M Rajala, Samuli Eldfors, Heikki Kuusanmäki, et al.
Nature Communications
|
April 21, 2018
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
Olli Dufva, Matti Kankainen, Tiina Kelkka, et al.
Biomarker Research
|
October 28, 2020
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia
Carlos Cuesta-Mateos, Patricia Fuentes, Alexandra Schrader, et al.
The New England Journal of Medicine
|
May 18, 2012
Somatic STAT3 mutations in large granular lymphocytic leukemia
Hanna L M Koskela, Samuli Eldfors, Pekka Ellonen, et al.
Page
of 1